ArgonautArgonautArgonautArgonaut
  • About Us
    • Business Model
    • Regulation
    • Community
    • Jason and the Argonauts
    • Disclaimer and Disclosure
    • COVID-19 Visitor Requirements
  • Corporate Finance
  • Stockbroking & Research
    • Stockbroking
    • Research
    • Best Execution Policy
    • Administration Forms
    • Open an Account
  • Special Situations
  • News
    • Latest News
    • Morning Notes
    • Latest Research
  • Contact
    • Careers
      • Advisers
      • Graduate Program
      • Internship Program

Dimerix (BXB) – DMX-200 Accelerated To A Phase 4 Covid-19 Study

    Home Latest Research Dimerix (BXB) – DMX-200 Accelerated To A Phase 4 Covid-19 Study
    NextPrevious

    Dimerix (BXB) – DMX-200 Accelerated To A Phase 4 Covid-19 Study

    By Wendy McEvoy | Latest Research | 0 comment | 9 June, 2020 | 0

    DXB’s CCR2 receptor blocker DMX-200 has been selected to take part in a WHO endorsed and externally funded global pandemic phase 4 study targeting Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. The study covers 200 global sites and involves up to 7,000 patients in an adaptive that if successful, could lead to the almost immediate commercialisation of DMX-200. There is no additional cost to DXB beyond supplying the drug to the study. We maintain our SPEC BUY recommendation and our price target is upgraded to $0.73 p/share.

    To access the full report please log in under the Client Area at the bottom of this page.

    Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.

    If you would like to access our research please contact us to create an account.

    No tags.

    Related Posts

    • MLG Oz (MLG) – Tuning In To FY24

      By Wendy McEvoy | 0 comment

      Weak margins and stretched balance sheet were focus areas when we recently initiated. While interim results highlighted margin recovery is still work in progress, the recent sale of idle crushing plants reduces leverage and addsRead more

    • Ramelius Resources (RMS) – Post Breaker

      By Wendy McEvoy | 0 comment

      We are tipping a resurrection of reputation with a good run of surplus cash flows for the rest of FY23 and into FY24, putting Ramelius in position to start developing post 2025 mine plans withRead more

    • GR Engineering (GNG) – Establishing A New Base

      By Wendy McEvoy | 0 comment

      Performances over the last four halves have been well ahead of those over the rest of the last decade. We expect this to establish a new, higher base for GNG, as its enhanced reputation andRead more

    • New Research – Sovereign Metals (SVM) – Kasiya Site Visit Insights

      By Wendy McEvoy | 0 comment

      We recently visited Sovereign Metals’ (SVM) giant Kasiya rutile and graphite project in Malawi. Development of Kasiya would be transformational for both SVM and the nation. Beyond the immediate financial benefits, Malawi would become aRead more

    • New Research – Global Lithium – Manna Study Dissection

      By Wendy McEvoy | 0 comment

      GL1 has reported the results of a Scoping Study for the Company’s flagship Manna project. While the study’s financial model generates an impressive Pre-tax NPV, in our view, the use of US$2,500/t sale price forRead more

    NextPrevious

    Recent Posts

    • 28/03/2023 – Morning Note
    • 27/03/2023 – Morning Note
    • 24/03/2023 – Morning Note
    • A$21.6 million Placement to ensure Catalyst is well-capitalised to advance exploration and development across the Plutonic-Marymia gold belt
    • MLG Oz (MLG) – Tuning In To FY24

    Archives

    • About Us
      • Business Model
      • Regulation
      • Community
      • Jason and the Argonauts
      • Disclaimer and Disclosure
      • COVID-19 Visitor Requirements
    • Corporate Finance
    • Stockbroking & Research
      • Stockbroking
      • Research
      • Best Execution Policy
      • Administration Forms
      • Open an Account
    • Special Situations
    • News
      • Latest News
      • Morning Notes
      • Latest Research
    • Contact
      • Careers
        • Advisers
        • Graduate Program
        • Internship Program
    Argonaut

    Argonaut | The Natural Choice in Resources.
    © 2022 Argonaut.

    Corporate Finance
    Stockbroking & Research
    Contact Us

    Argonaut | Perth

    Level 30, Allendale Square, 77 St Georges Terrace Perth, WA, 6000 Australia

    clientservices@argonaut.com

    ABN 72 108 330 650

    Argonaut | Login

    Client Area Help
    Register for Access to Client Area
    Privacy Policy
    Financial Services Guide 
    Website Disclaimer

    Copyright 2022 | Website ⚡ by Start Digital